← All drugs Report issue

opebacan

Recombinant proteinexperimental

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

2

Phase 3

0

Phase 4

0

Earliest trial started Apr 1, 2006 (NCT00462904)

Timeline

2000s

Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Jan 1, 2007
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Bactericidal permeability-increasing proteinINHIBITOR
BPI inhibitor
- Bactericidal permeability-increasing protein (BPI) ↗
Lipopolysaccharide (LPS)SEQUESTERING AGENT
Lipopolysaccharide (LPS) sequestering agent
Binding of opebacan to LPS precludes LPS binding to both lipopolysaccharide-binding protein (LBP) and LPS receptors such as TLR4, thus inhibiting LPS-induced inflammation, including TNF¿ production.

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL2107913 ↗

Also known as

opebacan
opebacan
rbpi-21

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00454155	Phase 1/Phase 2 (Phase 2)	Feb 1, 2007	Harvard University, Xoma
NCT00462904	Phase 2	Apr 1, 2006	The University of Texas, Dallas

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Harvard University	Academic/Hospital	1	0	1	2007
The University of Texas, Dallas	Academic/Hospital	1	1	1	2006
Xoma	For profit	1	1	1	2007

3 organizations

Page 1 / 1